Medication Overuse Headache Successfully Treated by Japanese Herbal Kampo Medicine, Yokukansan

Review began 09/17/2021
Review ended 09/20/2021
Published 09/27/2021

© Copyright 2021

Katsuki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Masahito Katsuki¹, Shin Kawamura¹, Kenta Kashiwagi², Akihito Koh¹

1. Department of Neurosurgery, Itoigawa General Hospital, Itoigawa, JPN 2. Department of Neurology, Itoigawa General Hospital, Itoigawa, JPN

Corresponding author: Akihito Koh, kohitoigawa@gmail.com

Abstract

Medication overuse headache (MOH) usually resolves after the overuse is stopped. However, it can be challenging to prescribe common prophylactic medications when patients are old or have concerns about the side effects of Western prophylactic medications. As an alternative therapy, traditional Japanese herbal Kampo medicine can be used. One of them, yokukansan (TJ-54), is often used for behavioral and psychological symptoms of dementia in Japan. Recently, it has been reported as an alternative medication for episodic, chronic, or MOH. We herein report a MOH in an older man already taking antihypertensive drugs. His MOH was successfully relieved by TJ-54 instead of the common prophylactic medications. His headache and nausea were relieved on day four of the treatment. After that, he did not need any analgesic drugs. Of course, we should pay attention to the side effects, pseudoaldosteronism, but TJ-54 may be one of the alternative treatment therapies for MOH.

Categories: Family/General Practice, Neurology, Pain Management

Keywords: japanese herbal medicine, kampo medicine, chronic migraine, chronic headache, alternative medical therapies, elderly, medication overuse headache (moh), yokukansan (tj-54)

Introduction

Medication overuse headache (MOH), coded 8.2 according to the International Classification of Headache Disorders 3rd edition (ICHD-3) [1], is a condition in which headaches occur 15 or more days per month in a patient with a pre-existing primary headache and develops as a consequence of regular overuse of acute or symptomatic headache medication (on 10 or more or 15 or more days per month, depending on the medication) for more than three months. The annual prevalence of MOH is 1-2% and it is common in middle-aged people and women. The headache usually resolves after the overuse is stopped [2]. According to the Japanese Clinical Practice Guideline for Chronic Headache 2013 [3], the treatment strategy is as follows: (a) discontinue the overused medication, (b) treat the headache after discontinuing the overused medication, and (c) administer prophylactic medications.

However, it can be challenging to prescribe common prophylactic medications like anticonvulsants and antidepressants for older MOH patients because of the side effects from prophylactic medications, such as drowsiness and allergies. As an alternative therapy, traditional Japanese herbal Kampo medicine can be used [3,4]. Yokukansan (TJ-54) is a traditional Japanese herbal Kampo medicine used to treat neurosis, insomnia, night crying, and irritability, and/or agitation in infants and is approved for prescription in Japan [5]. It is also often used in Japan for behavioral and psychological symptoms of dementia [6]. Recently, TJ-54 has been reported as an alternative therapy for episodic headache [7], chronic headache [5], or MOH [8,9], but such reports remain few. We herein report a MOH in an older man already taking antihypertensive drugs. His MOH was successfully relieved by TJ-54 instead of the common prophylactic medications.

Case Presentation

An 85-year-old man presented a chronic headache with a numeric rating scale (NRS) of 6/10 to our neurosurgical outpatient ward. The headache was not pulsatile but unilateral. There was no headache aggravation or avoidance of physical activity due to the headache, but nausea was present. The attacks lasted throughout the daytime. The patient had suffered from migraines since the age of 50 years, and he had been using over-the-counter medications. For the past two years, he had been taking three times daily 550-mg acetaminophen, 60-mg anhydrous caffeine, 270-mg salicylamide, and 13.5-mg promethazine methylene disalicylate as combination-analgesic medication from his family doctor. He also had hypertension and insomnia, so he took 20-mg olmesartan, 2.5-mg amlodipine, and 0.25-mg brotizolam as needed. Other than antihypertensive medication, he had never tried any prophylactic medications. The Hasegawa dementia scale-revised score was 26/30. The head CT and laboratory tests revealed that the headache did not seem to be secondary, so we diagnosed non-steroidal acetaminophen-overuse headache (ICHD-3 code 8.2.3.1), combination-analgesic-overuse headache (ICHD-3 code 8.2.5), and chronic migraine (ICHD-3 code 1.3). We stopped all the analgesic medications and let him keep a headache diary. Considering

How to cite this article

Katsuki M, Kawamura S, Kashiwagi K, et al. (September 27, 2021) Medication Overuse Headache Successfully Treated by Japanese Herbal Kampo Medicine, Yokukansan. Cureus 13(9): e18326. DOI 10.7759/cureus.18326

his older age and the side effects of using anticonvulsants or antidepressants as common prophylactic medications, we prescribed three packets of TJ-54 per day. His headache and nausea were relieved on day four of the treatment. He did not need any anti-inflammatory drugs in these 40 days, and we will continue TJ-54 (Figure 1). We are considering tapering off the dosage of TJ-54 every two weeks, ending the course in about two months.

FIGURE 1: Headache severity and the medication intake

After stopping the combination-analgesic medication and starting yokukansan (TJ-54), the severity gradually improved.

NRS: numerical rating scale

Discussion

We presented the case of an elderly man with MOH who was successfully treated using TJ-54. We used TJ-54 instead of common prophylactic medication because of the age of the patient and concerns regarding side effects. Although this is a single case report, TJ-54 seemed effective for MOH. Here, we review Kambo medicine for MOH and discuss how TJ-54 acts and what we should pay attention to.

TJ-54 for MOH

TJ-54 contains *Atractylodes lancea* rhizome (4.0 g), *Poria cocos* sclerotium (4.0 g), *Cnidium* rhizome (3.0 g), *Uncaria hook* (3.0 g), Japanese angelica root (3.0 g), *Bupleurum* root (2.0 g), and *Glycyrrhiza* (kanzo) (1.5 g). It is not commonly used to treat headaches and has not yet been recommended in the Japanese Clinical Practice Guideline for Chronic Headache 2013 [3]. However, in Japan, we often use TJ-54 to relieve the symptom related to dementia [6], and many Japanese clinicians may be familiar with its prescription. Previously, Mitsufuji reported three cases of MOH that were successfully treated by TJ-54 [8,9]. Of the three cases, one distrusted Western medication, one had irritability, and one had anxiety and depression. The first case continued TJ-54 for 16 days. The second and third cases continued TJ-54 but they did not clearly describe when TJ-54 would be stopped.

The mechanism of TJ-54 for headaches remains unclear. However, the following mechanisms have been reported: (a) suppression of neuronal excitation in the glutamatergic system through suppression of glutamate release action, which affects N-methyl-D-aspartic acid receptors, activation of glutamate transporters, adjustment of glutamate uptake, and suppression of increases in the extracellular glutamate level; (b) increased extracellular serotonin level in the serotonergic central nervous system through partial agonist effect on 5-HT1A receptors and downregulation of 5-HT1A receptors; (c) inhibition of orexin-A secretion; (d) anti-inflammatory effects; and (e) suppression of the microglia's activation in the spinal tract in the trigeminal nerve, which is important for the development of chronic migraine from episodic migraine [5,8,9]. These mechanisms collaboratively affect some of the central mechanisms in the trigeminovascular theory of migraine, and TJ-54 may relieve pain. Further research is needed.

Factors related to TJ-54 effectiveness

Kimura investigated the characteristics of episodic headaches that are relieved by TJ-54. Factors such as a decrease of painful eye sensation, back stiffness, eyestrain, and irritability were significant indicators of headache improvement. The three symptoms were the best subset of explanatory variables [7]. Our case had MOH, not an episodic headache, so further investigation is needed on what MOH patients are responsive to in TJ-54.

Side effects of TJ-54

Pseudoaldosteronism caused by Glycyrrhiza in TJ-54 is something to be aware of. According to the Japanese Adverse Drug Report (JADER) Database, the reporting odds ratio was 2.4 compared to other Glycyrrhiza-containing Kampo medicines. The dose amount, older age, low body weight, dementia are risk factors for pseudoaldosteronism [10]. Therefore, the TJ-54 dosage should be tapered according to symptoms, and a careful follow-up with a blood test will be needed. Also, the optimal duration of TJ-54 treatment for MOH should be investigated.

Other Kampo medicines for MOH

According to the Japanese Clinical Practice Guideline for Chronic Headache 2013, goshuyuto (TJ-31), keishininjinto (TJ-82), chotosan (TJ-47), kakkonto (TJ-1), and goreisan (TJ-17) are mentioned as empirically effective medications for headache treatment. We previously reported the efficacy of combined Kampo medicine treatment for a woman with MOH. The patient's migraine was associated with weather, menopause, and muscle tension, so we prescribed goreisan (TJ-17), goshuyuto (TJ-31), and kakkonto (TJ-1) for each characteristic of the headache [11]. Goreisan (TJ-17) may activate the glymphatic flow correctly and promote the drainage of inflammatory substances by regulating the aquaporin 4 channel, thereby suppressing the headache [12,13]. Goshuyuto (TJ-31) may adjust serotonin levels and vessel constriction appropriately [14,15], and raising serotonin levels beforehand by goshuyuto [16] may suppress the hyper-reactivity of serotonin receptors for serotonin, leading to the prevention of migraine attack. Kakkonto (TJ-1) may relieve tension-type headaches by upregulating blood flow in the shoulder muscles [17].

Akaishi used tokishakuyakusan (TJ-23) for a 42-year-old MOH woman and successfully relieved her headache [18]. Tokishakuyakusan is hypothesized to increase the estrogen and progesterone secretion from the ovary, possibly by activating the hypothalamic-pituitary-gonadal axis. In addition, daisaikoto (TJ-8), shosaikoto (TJ-9) [19], tokishigyakukagosyuyushokyo (TJ-38) [20] were also reported as useful alternative therapies for MOH as case reports. Further study on Kampo medicine for MOH is needed.

Our case report may lead to further robust studies like a randomized control trial using TJ-54 for MOH, which can help us have more options in treating patients like this. However, we need more data regarding traditional Japanese Kampo medicines. If these medications are found effective in further studies, we would also like to use them in treatment outside Japan.

Conclusions

We presented the case of MOH in an older man who was successfully treated using TJ-54, considering the old age and the side effect of other Western prophylactic medicines. Although this is a single case report, TJ-54 seemed effective for MOH treatment. Of course, we should pay attention to the side effects, pseudoaldosteronism, but TJ-54 could be considered as an alternative treatment therapy for MOH.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Itoigawa General Hospital Ethics Committee issued approval 2021-4. Our hospital's research ethics committee approved this study (ethical approval number 2021-4). We gained written informed consent for this study from the patient. All methods were carried out under relevant guidelines and regulations (Declaration of Helsinki). **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Cephalalgia: Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. 2018, 38:1-211. [10.1177/0333102417738202](https://doi.org/10.1177/0333102417738202)
2. Alstadhaug KB, Ofte HK, Kristoffersen ES: Preventing and treating medication overuse headache. *Pain Rep.* 2017, 2:e612. [10.1097/PR9.0000000000000612](https://doi.org/10.1097/PR9.0000000000000612)
3. Chronic Headache Clinical Practice Guideline Development Committee: Clinical Practice Guideline for

- Chronic Headache 2013. (2013). Accessed: 2021/9/11: <https://www.neurology-jp.org/guidelinem/ch/index.html>.
4. Katsuki M, Narita N, Matsumori Y, Ishida N, Watanabe O, Cai S, Tominaga T: Kampo (Japanese herbal) medicine for primary headache as an acute treatment - a retrospective investigation in Kesennuma City Hospital during five years [In Press]. *J Neurosurg Kampo Med.* 2022, 7:
 5. Akiyama H, Hasegawa Y: Effectiveness of the traditional Japanese Kampo medicine yokukansan for chronic migraine: a case report. *Medicine (Baltimore).* 2019, 98:e17000. [10.1097/MD.00000000000017000](https://doi.org/10.1097/MD.00000000000017000)
 6. Furukawa K, Tomita N, Uematsu D, et al.: Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. *Geriatr Gerontol Int.* 2017, 17:211-8. [10.1111/ggi.12696](https://doi.org/10.1111/ggi.12696)
 7. Kimura Y, Shimizu S, Tanaka A, Suzuki M, Kinebuchi A, Inaki K, Sato H: Efficacy of yokukansan-based prescriptions for the treatment of patients with headache [Article in Japanese]. *Kampo Med.* 2008, 59:265-71. [10.3937/kampomed.59.265](https://doi.org/10.3937/kampomed.59.265)
 8. Mitsufuji T, Yamamoto T, Hayashi Y, Mizoi Y, Tamura N, Araki N: Use of yokukansan for the treatment of medication overuse headache [Article in Japanese]. *J Japanese Assoc Orient Psychosom Med.* 2013, 28:47-9.
 9. Mitsufuji T, Yamamoto T, Miyake A, et al.: Use of yokukansan for the treatment of headaches caused by medication overuse, second report: effectiveness of administering only yokukansan [Article in Japanese]. *J Japanese Assoc Orient Psychosom Med.* 2014, 29:84-87.
 10. Ishida T, Kawada K, Morisawa S, Jobu K, Morita Y, Miyamura M: Risk factors for pseudoaldosteronism with yokukansan use: analysis using the Japanese Adverse Drug Report (JADER) database. *Biol Pharm Bull.* 2020, 45:1570-6. [10.1248/bpb.b20-00424](https://doi.org/10.1248/bpb.b20-00424)
 11. Katsuki M, Kawamura S, Kashiwagi K, Koh A: Medication overuse headache successfully treated by three types of Japanese herbal Kampo medicine. *Cureus.* 2021, 13:e16800. [10.7759/cureus.16800](https://doi.org/10.7759/cureus.16800)
 12. Shibata Y: Clinical analysis of the patients with primary headache in whom goreisan is effective [Article in Japanese]. *J Neurosurg kampo Med.* 2018, 4:9-13.
 13. Shibata Y, Ishiyama S: An analysis of the meteorological factors influencing climate-related headache and the clinical effects of goreisan [Article in Japanese]. *J Neurosurg kampo Med.* 2020, 6:26-32.
 14. Hibino T, Yuzurihara M, Terawaki K, Kanno H, Kase Y, Takeda A: Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. *J Pharmacol Sci.* 2008, 108:89-94. [10.1254/jphs.08058fp](https://doi.org/10.1254/jphs.08058fp)
 15. Hibino T, Yuzurihara M, Kanno H, Kase Y, Takeda A: Goshuyuto, a traditional Japanese medicine, and aqueous extracts of *Evodiae Fructus* constrict isolated rat aorta via adrenergic and/or serotonergic receptors. *Biol Pharm Bull.* 2009, 32:237-41. [10.1248/bpb.32.237](https://doi.org/10.1248/bpb.32.237)
 16. Odaguchi H, Wakasugi A, Ito H, Shoda H, Gono Y, Sakai F, Hanawa T: The efficacy of goshuyuto, a typical Kampo (Japanese herbal medicine) formula, in preventing episodes of headache. *Curr Med Res Opin.* 2006, 22:1587-97. [10.1185/030079906X112769](https://doi.org/10.1185/030079906X112769)
 17. Ara T, Sogawa N: Studies on Shokyo, Kanzo, and Keihi in Kakkonto medicine on prostaglandin E2 production in lipopolysaccharide-treated human gingival fibroblasts. *Int Sch Res Notices.* 2016, 2016:9351787. [10.1155/2016/9351787](https://doi.org/10.1155/2016/9351787)
 18. Akaishi T, Takayama S, Ohsawa M, et al.: Successful treatment of intractable menstrual migraine with the traditional herbal medicine tokishakuyakusan. *J Gen Fam Med.* 2019, 20:118-21. [10.1002/jgf2.242](https://doi.org/10.1002/jgf2.242)
 19. Kori K, Ohnaka M: Two cases of medication-overuse headache successfully treated with shosaikoto [Article in Japanese]. *Orient Med Pain Clin.* 2012, 42:10-3.
 20. Gono Y: Migraine: The role of Japanese kampo medicine in headache treatment [Article in Japanese]. *Igaku No Ayumi.* 2012, 243:1140-5.